Rhabdoid tumors as a novel target for PSMA-directed CAR T cell therapy

Molecular Therapy Oncology 2026 Open access

Read full text
Authors: Aroshi Mitra, Tianyi Zhou, Jacky Wu, Tran Nguyen, Chengtai Yu, Amrita Barua, Luping Huang, Xiaoting Jiang, Rajkumar Venkatramani, Moonsoo M. Jin, Bin He, Qin Fu Feng
DOI: 10.1016/j.omton.2026.201125
Cited by: 0
References: 29

Abstract

efficacy was also assessed in xenograft mouse models of non-CNS tumors, where PSMA CAR T cell treatment resulted in significant tumor regression and robust accumulation of CAR T cells within the tumor microenvironment. Together, these findings establish PSMA as a promising surface antigen beyond prostate cancer and provide preclinical evidence supporting the development of PSMA-directed therapies for this highly lethal pediatric cancer.

Fields of Study & Subjects

Chromatin Remodeling and Cancer Prostate Cancer Treatment and Research FOXO transcription factor regulation

Publication details

Journal / source
Molecular Therapy Oncology
Volume
34
Issue
1
Pages
201125–201125
Publication date
7 January 2026
Language
EN